Citigroup Inc Xenon Pharmaceuticals Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Xenon Pharmaceuticals Inc. stock. As of the latest transaction made, Citigroup Inc holds 3,838 shares of XENE stock, worth $148,338. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,838

Previous 2,413 59.06%

Holding current value

$148,338

Previous $103,000 44.66%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$36.25 - $43.75 $51,656 - $62,343	1,425 Added 59.06%	3,838 $149,000
Q1 2024 May 10, 2024	SELL	$42.66 - $50.04 $25,212 - $29,573	-591 Reduced 19.67%	2,413 $103,000
Q4 2023 Feb 09, 2024	BUY	$28.7 - $46.46 $3,960 - $6,411	138 Added 4.82%	3,004 $138,000
Q3 2023 Nov 09, 2023	SELL	$34.16 - $39.73 $43,998 - $51,172	-1,288 Reduced 31.01%	2,866 $97,000
Q2 2023 Aug 10, 2023	SELL	$34.84 - $43.54 $127,618 - $159,487	-3,663 Reduced 46.86%	4,154 $159,000
Q1 2023 May 11, 2023	BUY	$33.46 - $40.35 $201,027 - $242,422	6,008 Added 332.12%	7,817 $279,000
Q4 2022 Feb 09, 2023	BUY	$33.06 - $39.43 $3,041 - $3,627	92 Added 5.36%	1,809 $71,000
Q3 2022 Nov 10, 2022	SELL	$30.79 - $39.82 $6,188 - $8,003	-201 Reduced 10.48%	1,717 $62,000
Q2 2022 Aug 10, 2022	SELL	$25.44 - $35.16 $2.56 Million - $3.54 Million	-100,557 Reduced 98.13%	1,918 $58,000
Q1 2022 May 12, 2022	BUY	$25.09 - $33.13 $2.51 Million - $3.32 Million	100,174 Added 4353.5%	102,475 $3.13 Million
Q4 2021 Feb 10, 2022	SELL	$15.6 - $35.4 $5,116 - $11,611	-328 Reduced 12.48%	2,301 $72,000
Q3 2021 Nov 10, 2021	BUY	$14.86 - $19.45 $39,066 - $51,134	2,629 New	2,629 $40,000

Others Institutions Holding XENE

# of Institutions

221

Shares Held

69.6M

Call Options Held

59.7K

Put Options Held

60.7K

View Full List

About Xenon Pharmaceuticals Inc.

Ticker XENE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,263,500
Market Cap $2.41B
Description
Xenon Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel opener that is Phase III clinical trials for the treatment of KCNQ2 developmental and epilepsy encephalopath...

More about XENE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account